ГоловнаArchive of numbers2024Volume 32, issue 2 (119)The duration of cognitive changes which appeared simultaneously with emotional problems in an acute phase of coronavirus disease
Title of the article The duration of cognitive changes which appeared simultaneously with emotional problems in an acute phase of coronavirus disease
Authors Nikishkova Iryna
Kutikov Damir
Kutikov Oleksandr
Kizurina Julia
In the section MECHANISMS OF FORMATION AND MODERN PRINCIPLES OF TREATMENT OF NEUROLOGICAL DISORDERS
Year 2024 Issue Volume 32, issue 2 (119) Pages 22-27
Type of article Scientific article Index UDK 612.821.5:159.942:616.9-06-079 Index BBK -
Abstract DOI: https://doi.org/10.36927/2079-0325-V32-is2-2024-3

 Cognitive impairments, anxiety/depression and insomnia are ones of the most stable and exhausting consequences in the majority of persons who experiences SARS-CoV2 or another β-coronaviral infection. To evaluate a probability of maintenance of cognitive deficits associated with COVID-19 and to determine a type of connection between cognitive and emotional problems in different time points after the COVID-19 acute phase, by means of the group of survival analysis methods, an analysis of results of a remote survey of 111 persons (mean age of 27.83 ± 0.70 years old) with a positive result of PCR test for SARS-CoV2 and without any chronic disease was carried out. A prevalence of a sudden appearance of complaints regarding negative cognitive changes during the COVID-19 acute phase was 77.48 %, whereas of complaints regarding unusual emotional feelings was 67.57 %. A comparison of profiles of the function of a simultaneous appearance of cognitive and emotional changes during the COVID-19 acute phase demonstrated that one year after the COVID-19 acute phase a probability of maintenance of complaints regarding cognitions was 3 times lower in persons who have cognitive and emotional problems appeared simultaneously during the acute phase, whereas this probability was 5,5 times lower in persons who had no emotional changes during the acute phase. A comparison of profiles of the function of a simultaneous maintenance of cognitive and emotional problems has showed that persons with a steady combination of cognitive and emotional problems had a 1,5 times higher probability of maintenance of complaints regarding cognitions during 6 months after the COVID-19 acute phase, as compared with persons those unusual emotional feelings disappeared. Differences in the character of unusual emotional feelings did not reflect practically on a probability of an appearance of combinations of complaints regarding these feelings and cognitions during the COVID-19 acute phase, but the type of emotional feelings reflected significantly on the profile of the functions of a simultaneous maintenance of cognitive and emotional changes. To detect probable reasons of complaints about a sudden appearance of cognitive problems, which decrease the capacity to work and/or complicate everyday life, it is important not only to establish the fact of experience of SARSCoV2 and other β-coronaviral infections during the last 12 months, but also to make more precise an appearance during the disease and a duration of unusual emotional feelings, as this information strongly influences on the quality of results of the cognitive screening, a choice of methods and time for the neurocognitive rehabilitation, and an assessment of their efficacy.
Key words COVID-19, cognitive changes, emotional problems, cognitive screening
Access to full text version of the article pdf download
Bibliography 1. Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, Li J, Wang H, Yu L, Huang H, Qiu Y, Wei G, Fang Q, Zhou J, Sheng J, Liang T, Li L. [Management of COVID-19: the Zhejiang experience]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 Feb 21;49(2):147-157. Chinese. doi: 10.3785/j.issn.1008-9292.2020.02.02. PMID: 32391658; PMCID: PMC8800711.
2. Ermis U, Rust MI, Bungenberg J, Costa A, Dreher M, Balfanz P, Marx G, Wiesmann M, Reetz K, Tauber SC, Schulz JB. Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. Neurol Res Pract. 2021 Mar 12;3(1):17. doi: 10.1186/s42466-021-00116-1. PMID: 33712089; PMCID: PMC7953515.
3. Huang Y, Pinto MD, Borelli JL, Asgari Mehrabadi M, Abrahim HL, Dutt N, Lambert N, Nurmi EL, Chakraborty R, Rahmani AM, Downs CA. COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler Looking for Clarity in the Haze of the Pandemic. Clin Nurs Res. 2022 Nov;31(8):1390-1398. doi: 10.1177/10547738221125632. Epub 2022 Sep 24. PMID: 36154716; PMCID: PMC9510954.
4. Amalakanti S, Arepalli KVR, Jillella JP. Cognitive assessment in asymptomatic COVID-19 subjects. Virusdisease. 2021 Mar;32(1):146-149. doi: 10.1007/s13337-021-00663-w. Epub 2021 Feb 15. PMID: 33614860; PMCID: PMC7883942.
5. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep 2020;69:993-998. DOI: http://dx.doi.org/10.15585/ mmwr.mm6930e1. PMID: 32730238; PMCID: PMC7392393.
6. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8. Retracted and republished in: Lancet. 2023 Jun 17;401(10393):2025. doi: 10.1016/S0140-6736(23)01175-3. PMID: 33428867; PMCID: PMC7833295. 7. Huang L, Yao Q, Gu X, Wang Q, Ren L, Wang Y, Hu P, Guo L, Liu M, Xu J, Zhang X, Qu Y, Fan Y, Li X, Li C, Yu T, Xia J, Wei M, Chen L, Li Y, Xiao F, Liu D, Wang J, Wang X, Cao B. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021 Aug 28;398(10302):747-758. doi: 10.1016/S0140-6736(21)01755-4. Erratum in: Lancet. 2022 May 7;399(10337):1778. doi: 10.1016/S0140-6736(22)00795-4. PMID: 34454673; PMCID: PMC8389999. 8. Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, Liu M, Wang Y, Cui D, Wang Y, Zhang X, Shang L, Zhong J, Wang X, Wang J, Cao B. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022 Sep;10(9):863-876. doi: 10.1016/ S2213-2600(22)00126-6. Epub 2022 May 11. PMID: 35568052; PMCID: PMC9094732.
9. Woo MS, Malsy J, Pöttgen J, Seddiq Zai S, Ufer F, Hadjilaou A, Schmiedel S, Addo MM, Gerloff C, Heesen C, Schulze Zur Wiesch J, Friese MA. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020 Nov 23;2(2):fcaa205. doi: 10.1093/braincomms/fcaa205. PMID: 33376990; PMCID: PMC7717144.
10. Coleman B, Casiraghi E, Blau H, Chan L, Haendel MA, Laraway B, Callahan TJ, Deer RR, Wilkins KJ, Reese J, Robinson PN. Risk of new-onset psychiatric sequelae of COVID-19 in the early and late post-acute phase. World Psychiatry. 2022 Jun;21(2):319-320. doi: 10.1002/wps.20992. PMID: 35524622; PMCID: PMC9077621.
11. Liu, Yu-Hui & Wang, Ye-Ran & Wang, Qing-Hua & Chen, Yang & Chen, Xian & Li, Ying & Cen, Yuan & Xu, Cheng & Hu, Tian & Liu, Xu-Dong & Yang, Ling-Li & Li, Si-Jing & Liu, Xue-Fei & Liu, Chun-Mei & Zhu, Jie & Li, Wei & Zhang, Limin & Liu, Juan & Wang, Yan-Jiang. (2021). Post-infection cognitive impairments in a cohort of elderly patients with COVID-19. Molecular Neurodegeneration. 16. 10.1186/s13024-021-00469-w.
12. Tavares-Júnior JWL, de Souza ACC, Borges JWP, Oliveira DN, Siqueira-Neto JI, Sobreira-Neto MA, Braga-Neto P. COVID-19 associated cognitive impairment: A systematic review. Cortex. 2022 Jul;152:77-97. doi: 10.1016/j.cortex.2022.04.006. Epub 2022 Apr 18. PMID: 35537236; PMCID: PMC9014565.
13. Ritchie K, Chan D. The emergence of cognitive COVID. World Psychiatry. 2021 Feb;20(1):52-53. doi: 10.1002/wps.20837. PMID: 33432769; PMCID: PMC7801840.
14. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021 Jun;594(7862):259-264. doi: 10.1038/s41586-021-03553-9. Epub 2021 Apr 22. PMID: 33887749.
15. Duan K, Premi E, Pilotto A, Cristillo V, Benussi A, Libri I, Giunta M, Bockholt HJ, Liu J, Campora R, Pezzini A, Gasparotti R, Magoni M, Padovani A, Calhoun VD. Alterations of frontal-temporal gray matter volume associate with clinical measures of older adults with COVID-19. Neurobiol Stress. 2021 May;14:100326. doi: 10.1016/j.ynstr.2021.100326. Epub 2021 Apr 13. PMID: 33869679; PMCID: PMC8041745.
16. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, Walshaw C, Kemp S, Corrado J, Singh R, Collins T, O’Connor RJ, Sivan M. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021 Feb;93(2):1013-1022. doi: 10.1002/ jmv.26368. Epub 2020 Aug 17. PMID: 32729939.
17. Alemanno F, Houdayer E, Parma A, Spina A, Del Forno A, Scatolini A, Angelone S, Brugliera L, Tettamanti A, Beretta L, Iannaccone S. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience. PLoS One. 2021 Feb 8;16(2):e0246590. doi: 10.1371/ journal.pone.0246590. PMID: 33556127; PMCID: PMC7870071.
18. Bonizzato S, Ghiggia A, Ferraro F, Galante E. Cognitive, behavioral, and psychological manifestations of COVID-19 in post-acute rehabilitation setting: preliminary data of an observational study. Neurol Sci. 2022 Jan;43(1):51-58. doi: 10.1007/ s10072-021-05653-w. Epub 2021 Oct 12. PMID: 34642823; PMCID: PMC8510572.
19. Rogers JP, Chesney E, Oliver D, Pollak TA, McGuire P, Fusar-Poli P, Zandi MS, Lewis G, David AS. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020 Jul;7(7):611-627. doi: 10.1016/S2215-0366(20)30203-0. Epub 2020 May 18. PMID: 32437679; PMCID: PMC7234781.
20. Sheng B, Cheng SK, Lau KK, Li HL, Chan EL. The effects of disease severity, use of corticosteroids and social factors on neuropsychiatric complaints in severe acute respiratory syndrome (SARS) patients at acute and convalescent phases. Eur Psychiatry. 2005 May;20(3):236-42. doi: 10.1016/j.eurpsy.2004.06.023. PMID: 15935422; PMCID: PMC7135192.
21. Tsang HW, Scudds RJ, Chan EY. Psychosocial impact of SARS. Emerg Infect Dis. 2004 Jul;10(7):1326-7. doi: 10.3201/ eid1007.040090. PMID: 15338536; PMCID: PMC3323309.
22. Bechter K. Virus infection as a cause of inflammation in psychiatric disorders. Mod Trends Pharmacopsychiatry. 2013;28:49-60. doi: 10.1159/000343967. Epub 2013 Feb 27. PMID: 25224890. 23. Lam MH, Wing YK, Yu MW, Leung CM, Ma RC, Kong AP, So WY, Fong SY, Lam SP. Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Arch Intern Med. 2009 Dec 14;169(22):2142-7. doi: 10.1001/archinternmed.2009.384. PMID: 20008700.
24. https://lifelines.readthedocs.io/en/latest/index.html.
25. Нікішкова І. М., Кутіков Д. О., Кутіков О. Є., Кізюріна Ю. В. Особливості оцінки когнітивної ефективності при розсіяному склерозі. Український вісник психоневрології. [Nikishkova I. M., Kutikov D. O., Kutikov O. Ye., Kiziurina Yu. V.] [Peculiarities of assessment of cognitive efficiency in multiple sclerosis]. [Ukrainian Bulletin of Psychoneurology]. 2020;28; 3 (104):21—26. DOI: 10.36927/2079-0325-V28-Is3-2020-4. (In Ukrainian).